Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (153) 153
index medicus (146) 146
cardiac & cardiovascular systems (143) 143
female (119) 119
male (119) 119
aged (113) 113
abridged index medicus (100) 100
cardiovascular (96) 96
middle aged (92) 92
heart attacks (71) 71
treatment outcome (68) 68
atrial fibrillation (66) 66
mortality (64) 64
stroke (64) 64
risk factors (60) 60
acute coronary syndromes (56) 56
drug therapy (55) 55
anticoagulants (47) 47
cardiology (46) 46
risk (44) 44
follow-up studies (43) 43
clinical trials (42) 42
coronary heart disease (41) 41
cardiology and cardiovascular medicine (40) 40
warfarin (40) 40
anticoagulants - therapeutic use (38) 38
internal medicine (38) 38
analysis (37) 37
care and treatment (37) 37
double-blind method (37) 37
electrocardiography (35) 35
outcomes (35) 35
atrial fibrillation - complications (34) 34
cardiac arrhythmia (34) 34
cardiac patients (34) 34
stroke - prevention & control (34) 34
clopidogrel (33) 33
patients (33) 33
atrial fibrillation - drug therapy (31) 31
stroke - etiology (31) 31
studies (31) 31
aged, 80 and over (30) 30
myocardial infarction (30) 30
heart failure (28) 28
prevention (28) 28
time factors (28) 28
myocardial-infarction (27) 27
patient outcomes (27) 27
prognosis (27) 27
coronary vessels (26) 26
clinical medicine (25) 25
medical and health sciences (25) 25
medical colleges (25) 25
medicin och hälsovetenskap (25) 25
prospective studies (25) 25
acute coronary syndrome - drug therapy (24) 24
aspirin (24) 24
heart attack (24) 24
hospitalization (24) 24
incidence (24) 24
platelet aggregation inhibitors - therapeutic use (24) 24
cardiovascular disease (23) 23
diabetes (23) 23
hemorrhage - chemically induced (23) 23
ischemia (23) 23
medical research (23) 23
proportional hazards models (23) 23
registries (23) 23
therapy (22) 22
klinisk medicin (20) 20
medicine, experimental (20) 20
original research (20) 20
risk assessment (20) 20
rivaroxaban (20) 20
united states - epidemiology (20) 20
anticoagulants - adverse effects (19) 19
management (19) 19
administration, oral (18) 18
cardiovascular diseases (18) 18
dose-response relationship, drug (18) 18
fibrillation (18) 18
randomized controlled trials as topic (18) 18
retrospective studies (18) 18
thrombosis (18) 18
acute coronary syndrome (17) 17
anticoagulants - administration & dosage (17) 17
medicine, general & internal (17) 17
warfarin - therapeutic use (17) 17
cardiac and cardiovascular systems (16) 16
heart (16) 16
hemorrhage (16) 16
hypertension (16) 16
kardiologi (16) 16
myocardial infarction - therapy (16) 16
peripheral vascular disease (16) 16
platelet aggregation inhibitors - adverse effects (16) 16
transluminal angioplasty (16) 16
unstable angina (16) 16
article (15) 15
bleeding (15) 15
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
by Schwartz, Gregory G., MD, PhD and Bessac, Laurence, MD and Berdan, Lisa G., PA, MHS and Bhatt, Deepak L., MD, MPH and Bittner, Vera, MD and Diaz, Rafael, MD and Goodman, Shaun G., MD, MSc and Hanotin, Corinne, MD and Harrington, Robert A., MD and Jukema, J. Wouter, MD, PhD and Mahaffey, Kenneth W., MD and Moryusef, Angèle, MD and Pordy, Robert, MD and Roe, Matthew T., MD, MPH and Rorick, Tyrus, RN and Sasiela, William J., PhD and Shirodaria, Cheerag, MBBS and Szarek, Michael, PhD and Tamby, Jean-François, MD and Tricoci, Pierluigi, MD and White, Harvey, MBBS, DSc and Zeiher, Andreas, MD and Steg, Philippe Gabriel, MD
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 682 - 689.e1
Background Following acute coronary syndrome (ACS), the risk for future cardiovascular events is high and is related to levels of low-density lipoprotein... 
Cardiovascular | CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | EVENTS | CHOLESTEROL | EFFICACY | LDL | SAFETY | LOW-DENSITY-LIPOPROTEIN | RISK | HYPERCHOLESTEROLEMIA | ATORVASTATIN | Proprotein Convertases - antagonists & inhibitors | Heptanoic Acids - therapeutic use | Humans | Antibodies, Monoclonal - therapeutic use | Apolipoproteins B - blood | Hypercholesterolemia - drug therapy | Acute Coronary Syndrome - complications | Cholesterol, LDL - blood | Serine Endopeptidases | Drug Therapy, Combination | Pyrroles - therapeutic use | Stroke - prevention & control | Double-Blind Method | Rosuvastatin Calcium | Treatment Outcome | Hospitalization | Acute Coronary Syndrome - drug therapy | Atorvastatin Calcium | Anticholesteremic Agents - therapeutic use | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Angina, Unstable - prevention & control | Hypercholesterolemia - complications | Myocardial Infarction - prevention & control | Fluorobenzenes - therapeutic use | Proprotein Convertase 9 | Monoclonal antibodies | Analysis and chemistry | Coronary heart disease | Low density lipoproteins | Blood | Heart attacks | Mortality | Cardiovascular disease | Acute coronary syndromes | Drug therapy | Cholesterol
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
by Steg, Philippe Gabriel, Prof and Bhatt, Deepak L, Prof and Hamm, Christian W, Prof and Stone, Gregg W, MD and Gibson, C Michael, MD and Mahaffey, Kenneth W, MD and Leonardi, Sergio, MD and Liu, Tiepu, PhD and Skerjanec, Simona, PharmD and Day, Jonathan R, MD and Iwaoka, Robert S, MD and Stuckey, Thomas D, MD and Gogia, Harinder S, MD and Gruberg, Luis, MD and French, William J, MD and White, Harvey D, Prof and Harrington, Robert A, Prof and Champion Investigators and CHAMPION Investigators
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9909, pp. 1981 - 1992
Summary Background Cangrelor is a potent, rapid-acting, reversible intravenous platelet inhibitor that was tested for percutaneous coronary intervention (PCI)... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ISCHEMIC EVENTS | CLOPIDOGREL | UNIVERSAL DEFINITION | TICAGRELOR | CARDIOVASCULAR EVENTS | PLATELET INHIBITION | ASSOCIATION TASK-FORCE | PRASUGREL | ORAL ANTIPLATELET THERAPY | ELEVATION MYOCARDIAL-INFARCTION | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Adenosine Monophosphate - therapeutic use | Cause of Death | Randomized Controlled Trials as Topic | Myocardial Infarction - therapy | Graft Occlusion, Vascular - etiology | Percutaneous Coronary Intervention - methods | Adenosine Monophosphate - analogs & derivatives | Coronary Disease - therapy | Myocardial Ischemia - therapy | Acute Coronary Syndrome - therapy | Female | Myocardial Revascularization - statistics & numerical data | Aged | Hemorrhage - chemically induced | Platelet Aggregation Inhibitors - therapeutic use | Stents | Cangrelor | Drug therapy | Angioplasty | Patient outcomes | Heart attacks | Blood platelets | Coronary vessels | Acute coronary syndromes | Thrombosis | Veins & arteries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Factors Associated With Major Bleeding Events
by Goodman, Shaun G., MD, MSc and Wojdyla, Daniel M., MS and Piccini, Jonathan P., MD and White, Harvey D., MB, ChB, DSc and Paolini, John F., MD, PhD and Nessel, Christopher C., MD and Berkowitz, Scott D., MD and Mahaffey, Kenneth W., MD and Patel, Manesh R., MD and Sherwood, Matthew W., MD and Becker, Richard C., MD and Halperin, Jonathan L., MD and Hacke, Werner, MD and Singer, Daniel E., MD and Hankey, Graeme J., MD and Breithardt, Gunter, MD and Fox, Keith A.A., MB, ChB and Califf, Robert M., MD and ROCKET AF Investigators
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2014, Volume 63, Issue 9, pp. 891 - 900
Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with... 
Cardiovascular | Internal Medicine | anticoagulants | atrial fibrillation | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTORS | PREVENTION | ATRIAL-FIBRILLATION | ANTICOAGULATION | PREDICTION | STROKE | DABIGATRAN | WARFARIN | COMPLICATIONS | Heart | Sects | Medical colleges | Atrial fibrillation | Hypertension | Heart failure | Cardiac arrhythmia | Anticoagulants | Stroke | Embolisms | Nervous system | Risk factors | Confidence intervals | Hepatitis | Older people | Blood pressure | Diabetes | Drug therapy | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF
by Hankey, Graeme J, Prof and Patel, Manesh R, MD and Stevens, Susanna R, MSc and Becker, Richard C, MD and Breithardt, Günter, MD and Carolei, Antonio, Prof and Diener, Hans-Christoph, MD and Donnan, Geoffrey A, MD and Halperin, Jonathan L, Prof and Mahaffey, Kenneth W, MD and Mas, Jean-Louis, MD and Massaro, Ayrton, MD and Norrving, Bo, MD and Nessel, Christopher C, MD and Paolini, John F, MD and Roine, Risto O, MD and Singer, Daniel E, Prof and Wong, Lawrence, MD and Califf, Robert M, Prof and Fox, Keith AA, Prof and Hacke, Werner, MD and ROCKET AF Steering Comm and ROCKET AF Steering Committee Investigators and Lund University and Neurologi, Lund and Neurology, Lund and Lunds universitet
Lancet Neurology, The, ISSN 1474-4422, 2012, Volume 11, Issue 4, pp. 315 - 322
Summary Background In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial... 
Neurology | PREVENTION | TRIALS | THERAPY | EVENTS | CLINICAL NEUROLOGY | Stroke - prevention & control | Anticoagulants - administration & dosage | Double-Blind Method | Thiophenes - adverse effects | Atrial Fibrillation - drug therapy | Humans | Morpholines - administration & dosage | Warfarin - adverse effects | Treatment Outcome | Secondary Prevention | Thiophenes - administration & dosage | Anticoagulants - adverse effects | Warfarin - administration & dosage | Rivaroxaban | Ischemic Attack, Transient - prevention & control | Multicenter Studies as Topic | Intention to Treat Analysis | Aged | Morpholines - adverse effects | Medical colleges | Care and treatment | Warfarin | Atrial fibrillation | Abnormalities | Singers | Anticoagulants (Medicine) | Muscle contraction | Stroke (Disease) | Ischemia | Analysis | Comparative analysis | Cardiology | Stroke | Fibrillation | Transient ischemic attack | Motivation | Bleeding | Embolism | Pharmaceuticals | Neurologi | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial
by Piccini, Jonathan P., MD, MHS and Stevens, Susanna R., MS and Lokhnygina, Yuliya, PhD and Patel, Manesh R., MD and Halperin, Jonathan L., MD and Singer, Daniel E., MD and Hankey, Graeme J., MD and Hacke, Werner, MD, PhD and Becker, Richard C., MD and Nessel, Christopher C., MD and Mahaffey, Kenneth W., MD and Fox, Keith A.A., MB, ChB and Califf, Robert M., MD and Breithardt, Günter, MD and ROCKET AF Steering Comm Investigat and ROCKET AF Steering Committee & Investigators
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2013, Volume 61, Issue 19, pp. 1998 - 2006
Objectives This study sought to investigate the outcomes following cardioversion or catheter ablation in patients with atrial fibrillation (AF) treated with... 
Cardiovascular | Internal Medicine | atrial fibrillation | catheter ablation | rivaroxaban | stroke | cardioversion | warfarin | PREDICTING STROKE | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | RISK | ANTICOAGULATION | TASK-FORCE | THROMBOEMBOLISM | ASSOCIATION | Multivariate Analysis | Thiophenes - therapeutic use | Catheter Ablation - statistics & numerical data | Stroke - prevention & control | Atrial Fibrillation - therapy | Humans | Middle Aged | Anticoagulants - therapeutic use | Male | Treatment Outcome | Electric Countershock - statistics & numerical data | Warfarin - therapeutic use | Rivaroxaban | Multicenter Studies as Topic | Female | Stroke - epidemiology | Aged | Morpholines - therapeutic use | Sects | Medical colleges | Care and treatment | Ablation (Surgery) | Warfarin | Atrial fibrillation | Patient outcomes | Clinical trials | Electric countershock | Cardiac arrhythmia | Stroke | Heart attacks | Drug therapy | Older people
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
by Neal, Bruce, PhD and Perkovic, Vlado, PhD and de Zeeuw, Dick, PhD and Mahaffey, Kenneth W., MD and Fulcher, Greg, MD and Stein, Peter, MD and Desai, Mehul, MD and Shaw, Wayne, DSL and Jiang, Joel, PhD and Vercruysse, Frank, MD and Meininger, Gary, MD and Matthews, David, DPhil and CANVAS Trial Collaborative Grp
American Heart Journal, ISSN 0002-8703, 2013, Volume 166, Issue 2, pp. 217 - 223.e11
Sodium glucose co-transporter 2 inhibition is a novel mode of treatment for type 2 diabetes mellitus (T2DM). The sodium glucose co-transporter 2 inhibitor... 
Cardiovascular | GLUCOSE | TUBULAR REABSORPTION | CARDIAC & CARDIOVASCULAR SYSTEMS | Hypoglycemic Agents - therapeutic use | Thiophenes - therapeutic use | Double-Blind Method | Thiophenes - adverse effects | Humans | Middle Aged | Male | Biomarkers - blood | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Canagliflozin | Cardiovascular Diseases - mortality | Electrocardiography | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Research Design | Glucosides - adverse effects | Type 2 diabetes | Clinical trials | Hemoglobin | Glucose metabolism | Blood sugar | Health aspects | Hypertension | Heart failure | Plasma | Body mass index | Rodents | Cardiovascular disease | Triglycerides | Glucose | Diabetes | Drug therapy | Statins | Regulatory approval
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry
by Pokorney, Sean D., MD, MBA and Simon, DaJuanicia N., MS and Thomas, Laine, PhD and Fonarow, Gregg C., MD and Kowey, Peter R., MD and Chang, Paul, MD and Singer, Daniel E., MD, MA and Ansell, Jack, MD and Blanco, Rosalia G., BA and Gersh, Bernard, MB, ChB, DPhil and Mahaffey, Kenneth W., MD and Hylek, Elaine M., MD, MPH and Go, Alan S., MD and Piccini, Jonathan P., MD, MHS and Peterson, Eric D., MD, MPH and ORBIT-AF Investigators and Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators
American Heart Journal, ISSN 0002-8703, 2015, Volume 170, Issue 1, pp. 141 - 148.e1
Background Time in therapeutic range (TTR) of international normalized ratio (INR) of 2.0 to 3.0 is important for the safety and effectiveness of warfarin... 
Cardiovascular | UNITED-STATES | CARDIAC & CARDIOVASCULAR SYSTEMS | QUALITY | STROKE PREVENTION | EFFICACY | ORAL ANTICOAGULATION | ALGORITHM | INTENSITY | RISK | NORMALIZED RATIO CONTROL | OUTCOMES | United States | Humans | Middle Aged | Male | Warfarin - therapeutic use | Renal Insufficiency, Chronic - epidemiology | Time Factors | Aged, 80 and over | Female | Registries | Heart Failure - epidemiology | Stroke - prevention & control | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Logistic Models | Treatment Outcome | Frail Elderly | International Normalized Ratio | Heart Valve Prosthesis Implantation - statistics & numerical data | Stroke - etiology | Atrial Fibrillation - epidemiology | Aged | Health aspects | Warfarin | Atrial fibrillation | Studies | Variables | Anticoagulants | Demographics | Research & development--R&D | Laboratories | Population | Clinical medicine | Family medical history | Kidney diseases | Pharmaceutical industry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
by Abraham, Neena S., MD, FACG and Hlatky, Mark A., MD, FACC, FAHA and Antman, Elliott M., MD, FACC, FAHA and Bhatt, Deepak L., MD, MPH, FACC, FAHA and Bjorkman, David J., MD, MSPH, FACG and Clark, Craig B., DO, FACC, FAHA and Furberg, Curt D., MD, PhD, FAHA and Johnson, David A., MD, FACG and Kahi, Charles J., MD, MSc, FACG and Laine, Loren, MD, FACG and Mahaffey, Kenneth W., MD, FACC and Quigley, Eamonn M., MD, FACG and Scheiman, James, MD, FACG and Sperling, Laurence S., MD, FACC, FAHA and Tomaselli, Gordon F., MD, FACC, FAHA
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2010, Volume 56, Issue 24, pp. 2051 - 2066
  Often, the topic is the subject of considerable ongoing investigation. [...]the reader should view the expert consensus document as the best attempt of the... 
Cardiovascular | Internal Medicine | proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | ACCF Expert Consensus Document | thienopyridine | Aspirin | Gastrointestinal hemorrhage | Antiplatelet drugs | Platelet aggregation inhibitors | Proton pump inhibitors | Thienopyridine | Usage | Nonsteroidal anti-inflammatory drugs | Heart | Task forces | Heart attacks | Mortality | Metabolism | Disclosure | Thrombosis | Confidence intervals | Gastroenterology | Writing | Clinical medicine | Drug therapy | Acute coronary syndromes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention
by Vaduganathan, Muthiah, MD, MPH and Harrington, Robert A., MD and Stone, Gregg W., MD and Deliargyris, Efthymios N., MD and Steg, Ph. Gabriel, MD and Gibson, C. Michael, MS, MD and Hamm, Christian W., MD and Price, Matthew J., MD and Menozzi, Alberto, MD and Prats, Jayne, PhD and Elkin, Steven, MS and Mahaffey, Kenneth W., MD and White, Harvey D., DSc and Bhatt, Deepak L., MD, MPH and CHAMPION Investigators
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 2, pp. 176 - 185
Abstract Background Cangrelor, an intravenous, reversible P2Y12 antagonist, is approved for use in patients undergoing percutaneous coronary intervention... 
Cardiovascular | Internal Medicine | coronary artery disease | bleeding | antiplatelet therapy | outcomes | CARDIAC & CARDIOVASCULAR SYSTEMS | PRIMARY PCI | BIVALIRUDIN | IMPAIRED BIOAVAILABILITY | CHAMPION PHOENIX | CLOPIDOGREL | PLATELET INHIBITION | BLOOD-TRANSFUSION | ELEVATION MYOCARDIAL-INFARCTION | INSIGHTS | Prospective Studies | Ticlopidine - therapeutic use | Humans |